Serum adiponectin and protein–energy wasting in predialysis chronic kidney disease

Nutrition

Volumn 33, Issue , 2017, Pages 254-260

  Hyun, Young Youl ^a   Lee, Kyu Beck ^a   Oh, Kook Hwan ^b   Ahn, Curie ^a   Park, Sue Kyung ^c   Chae, Dong Wan ^d   Yoo, Tae Hyun ^e   Cho, Kyu Hun ^e   Kim, Yong Soo ^f   Hwang, Young Hwan ^g  

^a School of Medicine   (South Korea)

^b Seoul National University Hospital   (South Korea)

^c Seoul National University College of Medicine   (South Korea)

^d Seoul National University Bundang Hospital   (South Korea)

^e Yonsei University College of Medicine   (South Korea)

^f The Catholic University of Korea   (South Korea)

^g Eulji General Hospital   (South Korea)

Author keywords

Adiponectin; Chronic kidney disease; Protein energy wasting; Urine creatinine excretion

Indexed keywords

ADIPONECTIN; CREATININE; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; PARATHYROID HORMONE; SERUM ALBUMIN; ADIPOQ PROTEIN, HUMAN; BIOLOGICAL MARKER;

ADULT; AGED; ARTICLE; ATHEROGENESIS; BODY MASS; CHRONIC KIDNEY DISEASE; COMORBIDITY; CONFIDENCE INTERVAL; CORRELATION ANALYSIS; CREATININE URINE LEVEL; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; ESTIMATED GLOMERULAR FILTRATION RATE; FEMALE; HEART FAILURE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MULTIPLE LINEAR REGRESSION ANALYSIS; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; ODDS RATIO; PREDIALYSIS CHRONIC KIDNEY DISEASE; PREVALENCE; PRIORITY JOURNAL; PROTEIN CALORIE MALNUTRITION; PROTEIN INTAKE; PROTEINURIA; RISK FACTOR; SOCIOECONOMICS; BLOOD; CLINICAL TRIAL; COHORT ANALYSIS; KIDNEY; MIDDLE AGED; MULTICENTER STUDY; PATHOPHYSIOLOGY; PROSPECTIVE STUDY; PROTEIN-ENERGY MALNUTRITION; RENAL INSUFFICIENCY, CHRONIC; SEVERITY OF ILLNESS INDEX; SOUTH KOREA; UNIVERSITY HOSPITAL; UPREGULATION; URINE;

ADIPONECTIN; ADULT; AGED; BIOMARKERS; COHORT STUDIES; COMORBIDITY; CREATININE; CROSS-SECTIONAL STUDIES; FEMALE; HOSPITALS, UNIVERSITY; HUMANS; KIDNEY; MALE; MIDDLE AGED; PREVALENCE; PROSPECTIVE STUDIES; PROTEIN-ENERGY MALNUTRITION; RENAL INSUFFICIENCY, CHRONIC; REPUBLIC OF KOREA; RISK FACTORS; SEVERITY OF ILLNESS INDEX; UP-REGULATION;

EID: 85003706957     PISSN: 08999007     EISSN: 18731244     Source Type: Journal    
DOI: 10.1016/j.nut.2016.06.014     Document Type: Article

References (36)

1. [1] Jha, V., Garcia-Garcia, G., Iseki, K., Li, Z., Naicker, S., Plattner, B., et al. Chronic kidney disease: global dimension and perspectives. Lancet 382 (2013), 260–272.
2. [2] Ikizler, T.A., Cano, N.J., Franch, H., Fouque, D., Himmelfarb, J., Kalantar-Zadeh, K., et al. Prevention and treatment of protein energy wasting in chronic kidney disease patients: a consensus statement by the International Society of Renal Nutrition and Metabolism. Kidney Int 84 (2013), 1096–1107.
3. [3] Fouque, D., Kalantar-Zadeh, K., Kopple, J., Cano, N., Chauveau, P., Cuppari, L., et al. A proposed nomenclature and diagnostic criteria for protein-energy wasting in acute and chronic kidney disease. Kidney Int 73 (2008), 391–398.
4. [4] Fantuzzi, G., Adiponectin in inflammatory and immune-mediated diseases. Cytokine 64 (2013), 1–10.
5. [5] Han, S.H., Quon, M.J., Kim, J.A., Koh, K.K., Adiponectin and cardiovascular disease: response to therapeutic interventions. J Am Coll Cardiol 49 (2007), 531–538.
6. [6] Lihn, A.S., Pedersen, S.B., Richelsen, B., Adiponectin: action, regulation and association to insulin sensitivity. Obes Rev 6 (2005), 13–21.
7. [7] Qi, Y., Takahashi, N., Hileman, S.M., Patel, H.R., Berg, A.H., Pajvani, U.B., et al. Adiponectin acts in the brain to decrease body weight. Nat Med 10 (2004), 524–529.
8. [8] Kishida, K., Funahashi, T., Shimomura, I., Adiponectin as a routine clinical biomarker. Best Pract Res Clin Endocrinol Metab 28 (2014), 119–130.
9. [9] Kistorp, C., Faber, J., Galatius, S., Gustafsson, F., Frystyk, J., Flyvbjerg, A., et al. Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure. Circulation 112 (2005), 1756–1762.
10. [10] Wu, Z.J., Cheng, Y.J., Gu, W.J., Aung, L.H., Adiponectin is associated with increased mortality in patients with already established cardiovascular disease: a systematic review and meta-analysis. Metabolism 63 (2014), 1157–1166.
11. [11] Yamauchi, T., Kadowaki, T., Adiponectin receptor as a key player in healthy longevity and obesity-related diseases. Cell Metab 17 (2013), 185–196.
12. [12] Chandran, M., Phillips, S.A., Ciaraldi, T., Henry, R.R., Adiponectin: more than just another fat cell hormone?. Diabetes Care 26 (2003), 2442–2450.
13. [13] Liu, Y., Sweeney, G., Adiponectin action in skeletal muscle. Best Pract Res Clin Endocrinol Metab 28 (2014), 33–41.
14. [14] Huang, C., Tomata, Y., Kakizaki, M., Sugawara, Y., Hozawa, A., Momma, H., et al. High circulating adiponectin levels predict decreased muscle strength among older adults aged 70 years and over: a prospective cohort study. Nutr Metab Cardiovasc Dis 25 (2015), 594–601.
15. [15] Loncar, G., Bozic, B., von Haehling, S., Dungen, H.D., Prodanovic, N., Lainscak, M., et al. Association of adiponectin with peripheral muscle status in elderly patients with heart failure. Eur J Intern Med 24 (2013), 818–823.
16. [16] Martinez Cantarin, M.P., Waldman, S.A., Doria, C., Frank, A.M., Maley, W.R., Ramirez, C.B., et al. The adipose tissue production of adiponectin is increased in end-stage renal disease. Kidney Int 83 (2013), 487–494.
17. [17] Menon, V., Li, L., Wang, X., Greene, T., Balakrishnan, V., Madero, M., et al. Adiponectin and mortality in patients with chronic kidney disease. J Am Soc Nephrol 17 (2006), 2599–2606.
18. [18] Drechsler, C., Krane, V., Winkler, K., Dekker, F.W., Wanner, C., Changes in adiponectin and the risk of sudden death, stroke, myocardial infarction, and mortality in hemodialysis patients. Kidney Int 76 (2009), 567–575.
19. [19] Rhee, C.M., Nguyen, D.V., Moradi, H., Brunelli, S.M., Dukkipati, R., Jing, J., et al. Association of adiponectin with body composition and mortality in hemodialysis patients. Am J Kidney Dis 66 (2015), 313–321.
20. [20] Oh, K.H., Park, S.K., Park, H.C., Chin, H.J., Chae, D.W., Choi, K.H., et al. KNOW-CKD (KoreaN cohort study for Outcome in patients With Chronic Kidney Disease): design and methods. BMC Nephrol, 15, 2014, 80.
21. [21] Masud, T., Manatunga, A., Cotsonis, G., Mitch, W.E., The precision of estimating protein intake of patients with chronic renal failure. Kidney Int 62 (2002), 1750–1756.
22. [22] Levin, A., Stevens, P.E., Summary of KDIGO 2012 CKD Guideline: behind the scenes, need for guidance, and a framework for moving forward. Kidney Int 85 (2014), 49–61.
23. [23] Yamauchi, T., Kamon, J., Waki, H., Terauchi, Y., Kubota, N., Hara, K., et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 7 (2001), 941–946.
24. [24] Arita, Y., Kihara, S., Ouchi, N., Maeda, K., Kuriyama, H., Okamoto, Y., et al. Adipocyte-derived plasma protein adiponectin acts as a platelet-derived growth factor-BB-binding protein and regulates growth factor-induced common postreceptor signal in vascular smooth muscle cell. Circulation 105 (2002), 2893–2898.
25. [25] Tao, L., Gao, E., Jiao, X., Yuan, Y., Li, S., Christopher, T.A., et al. Adiponectin cardioprotection after myocardial ischemia/reperfusion involves the reduction of oxidative/nitrative stress. Circulation 115 (2007), 1408–1416.
26. [26] Chen, H., Montagnani, M., Funahashi, T., Shimomura, I., Quon, M.J., Adiponectin stimulates production of nitric oxide in vascular endothelial cells. J Biol Chem 278 (2003), 45021–45026.
27. [27] Pischon, T., Girman, C.J., Hotamisligil, G.S., Rifai, N., Hu, F.B., Rimm, E.B., Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 291 (2004), 1730–1737.
28. [28] Poehls, J., Wassel, C.L., Harris, T.B., Havel, P.J., Swarbrick, M.M., Cummings, S.R., et al. Association of adiponectin with mortality in older adults: the Health, Aging, and Body Composition study. Diabetologia 52 (2009), 591–595.
29. [29] Sook Lee, E., Park, S.S., Kim, E., Sook Yoon, Y., Ahn, H.Y., Park, C.Y., et al. Association between adiponectin levels and coronary heart disease and mortality: a systematic review and meta-analysis. Int J Epidemiol 42 (2013), 1029–1039.
30. [30] Matsumoto, M., Ishikawa, S., Kajii, E., Adiponectin and noncardiovascular death: a nested case-control study. Metabolism 57 (2008), 811–818.
31. [31] Van Berendoncks, A.M., Garnier, A., Beckers, P., Hoymans, V.Y., Possemiers, N., Fortin, D., et al. Functional adiponectin resistance at the level of the skeletal muscle in mild to moderate chronic heart failure. Circ Heart Fail 3 (2010), 185–194.
32. [32] Van Berendoncks, A.M., Garnier, A., Ventura-Clapier, R., Conraads, V.M., Adiponectin: key role and potential target to reverse energy wasting in chronic heart failure. Heart Fail Rev 18 (2013), 557–566.
33. [33] Kollerits, B., Fliser, D., Heid, I.M., Ritz, E., Kronenberg, F., Gender-specific association of adiponectin as a predictor of progression of chronic kidney disease: the Mild to Moderate Kidney Disease study. Kidney Int 71 (2007), 1279–1286.
34. [34] Park, S.H., Carrero, J.J., Lindholm, B., Stenvinkel, P., Adiponectin in chronic kidney disease has an opposite impact on protein-energy wasting and cardiovascular risk: two sides of the same coin. Clin Nephrol 72 (2009), 87–96.
35. [35] Siew, E.D., Ikizler, T.A., Insulin resistance and protein energy metabolism in patients with advanced chronic kidney disease. Semin Dial 23 (2010), 378–382.
36. [36] Carrero, J.J., Stenvinkel, P., Cuppari, L., Ikizler, T.A., Kalantar-Zadeh, K., Kaysen, G., et al. Etiology of the protein-energy wasting syndrome in chronic kidney disease: a consensus statement from the International Society of Renal Nutrition and Metabolism (ISRNM). J Ren Nutr 23 (2013), 77–90.